What are the blue-chip highlights?
Clothing retailer American Apparel was given the green light to exit bankruptcy, and now a group of hedge funds are set to takeover the group.
Elsewhere, investors in Twitter (NYSE:TWTR) were spooked by exodus of executives has raised concerns about the microblogging company’s plans to win more users.
And, the so-called surprise of the day is apparent implication that fast food customers are happier to eat breakfast late (perhaps they prefer to sleep in). McDonald’s (NYSE:MCD) today revealed better than expected results for the fourth quarter, with it performance boosted by it new all-day breakfast policy.
Why The Fluctuations?
Here are Monday’s notable movers without news.
Viggle, the marketing group for online entertainment, shot up nearly 40% to trade at US$0.43 per share.
Shares in Grizzly Gold, a Nevada focussed prospecting firm, roared some 150% higher to 1.75 cents each.
The Naked Brand Group, a clothing company which says wearing its underwear “is a lot like” sliding into the leather seat of a luxury sports car, lost a quarter of its horsepower on the Nasdaq, falling to US$2.16.
Elsewhere, the stocks on the move with discernible news included:
Risers
Catabasis Pharma (NASDAQ:CATB) up 17.2% to US$6.81 after the clinical-stage drug development company unveiled positive top-line results an early trial for CAT-1004 for the treatment of Duchenne muscular dystrophy.
Rosetta Genomics (NASDAQ:ROSG), up 10.6% to US$0.94, got a boost from a US patent allowance for the use of gene expression signature for the classification of kidney tumors.
BioLineRx (NASDAQ:BLRX) up 4.9% to US$1.08, thanks to confirmation of a medical device classification in Europe for its celiac treatment BL-7010.
Raptor Pharma (NASDAQ:RPTP) up 13.2% to US$3.91, as it obtained a fifth patent for PROCYSBI in the FDA Orange Book.
Cray (NASDAQ:CRAY), up 11.6% to US$36.90, with news of a US$36mln contract to upgrade systems at the European Centre for Medium-Range Weather Forecasts (ECMWF).
Cytori Therapeutics (NASDAQ:CYTX) up 7.1% to US$0.187, due to an update on a after the Phase 3 trial, which has now enrolled and treated its 20th patient, or 25% of target enrollment.
Fallers:
Novavax (NASDAQ:NVAX) down 2% to US$6.49. after the clinical-stage vaccine company revealed plans to raise $200mln via an issue of convertible senior unsecured notes.
Oncomed Pharmaceuticals (NASDAQ:OMED) fell 42% to just over US$10, after warning investors that independent data monitoring of a Phase 2 drug trial indicated the study was becoming futile.